Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topical mitomycin-C for pterygia: is single application appropriate?

R S Rubinfeld1, R M Stein

  • 1Department of Ophthalmology/Center for Sight, Georgetown University Medical Center, Washington, DC, USA.

Ophthalmic Surgery and Lasers
|August 1, 1997
PubMed
Summary

Mitomycin-C significantly reduces pterygium recurrence, especially with intraoperative application combined with conjunctival closure. Lower dosages and shorter durations increase recurrence rates, highlighting the need for careful dosing strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methicillin-resistant Staphylococcus aureus ulcerative keratitis after laser in situ keratomileusis.

Journal of cataract and refractive surgery·2001
Same author

Case reports and small case series: LASIK-associated visual field loss in a glaucoma suspect.

Archives of ophthalmology (Chicago, Ill. : 1960)·2001
Same author

Ocular deposition of copper associated with multiple myeloma.

American journal of ophthalmology·2001
Same author

Latino physician supply in California: sources, locations, and projections.

Academic medicine : journal of the Association of American Medical Colleges·2000
Same author

Communicating with laser vision correction patients.

Journal of ophthalmic nursing & technology·2000
Same author

Corneal cooling and rehydration during photorefractive keratectomy to reduce postoperative corneal haze.

Journal of refractive surgery (Thorofare, N.J. : 1995)·1999

Area of Science:

  • Ophthalmology
  • Surgical Oncology
  • Pharmacology

Background:

  • Mitomycin-C (MMC) is effective in reducing pterygium recurrence.
  • High cumulative doses of MMC are linked to serious complications.
  • Investigating reduced MMC dosages is crucial for safety and efficacy.

Purpose of the Study:

  • To evaluate the safety and efficacy of varying Mitomycin-C dosages for pterygium surgery.
  • To determine optimal MMC dosing to minimize recurrence and complications.

Main Methods:

  • Prospective nonrandomized trial involving 481 pterygium excisions.
  • Utilized five distinct Mitomycin-C dosages and treatment durations.
  • Defined recurrence as fibrovascular tissue regrowth onto the cornea.

Related Experiment Videos

Main Results:

  • Control group (no MMC) had a 65% recurrence rate.
  • 0.4 mg/ml MMC for 2 weeks yielded 2.5% recurrence but 10% complications.
  • Intraoperative 0.2 mg/ml MMC with conjunctival closure showed 2.7% recurrence and no complications.

Conclusions:

  • Intraoperative Mitomycin-C with conjunctival closure is highly effective in preventing pterygium recurrence.
  • Lower dosages or shorter durations may increase recurrence rates.
  • Surgeons must exercise caution due to MMC's potency and the need for further randomized trials.